<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401918</url>
  </required_header>
  <id_info>
    <org_study_id>40761</org_study_id>
    <nct_id>NCT03401918</nct_id>
  </id_info>
  <brief_title>Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility</brief_title>
  <official_title>Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if patients with recurrent pregnancy loss or&#xD;
      unexplained infertility have an altered uterine gene expression or uterine microbiome&#xD;
      (micro-organism composition) during the window of embryo implantation. Furthermore we would&#xD;
      like to assess for women with an abnormal uterine gene expression whether vaginal&#xD;
      progesterone medication improves or alters gene expression and for women with an abnormal&#xD;
      microbiome whether antibiotic treatment followed by probiotic treatment normalizes the&#xD;
      microbiome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent pregnancy loss and unexplained infertility are emotional and difficult diagnoses.&#xD;
      Despite a thorough medical investigation, many cases of recurrent pregnancy loss and&#xD;
      infertility remain unexplained. Understanding endometrial factors that may contribute to&#xD;
      these diseases may lead to improved treatment options in the future. The purpose of this&#xD;
      study is to determine if patients with recurrent pregnancy loss or unexplained infertility&#xD;
      have an altered uterine gene expression or uterine microbiome (micro-organism composition)&#xD;
      during the window of embryo implantation. Furthermore we would like to assess for women with&#xD;
      an abnormal uterine gene expression whether vaginal progesterone medication improves or&#xD;
      alters gene expression and for women with an abnormal microbiome whether antibiotic treatment&#xD;
      followed by probiotic treatment normalizes the microbiome.&#xD;
&#xD;
      A standard evaluation for infertility includes a uterine cavity evaluation, evaluation for&#xD;
      ovarian reserve testing, and for patients with recurrent pregnancy loss parental testing for&#xD;
      uterine infection, chromosome analysis, autoimmune and thyroid screening. This standard&#xD;
      workup, however, does not include a molecular or microbial assessment of the endometrium.&#xD;
      Endometrial factors may contribute to unexplained infertility or recurrent pregnancy loss&#xD;
      however the extent of this is unknown.&#xD;
&#xD;
      We are recruiting patients who have recurrent pregnancy loss, unexplained infertility, and&#xD;
      healthy control patients who have had a term delivery in order to compare differences between&#xD;
      these groups.&#xD;
&#xD;
      Subjects will undergo an endometrial biopsy that will specifically test the receptivity of&#xD;
      your endometrium as well as identify the bacterial composition of the uterine environment&#xD;
      (microbiome). The endometrial receptivity array and microbiome testing will be performed at&#xD;
      no cost. The endometrial receptivity array provides information on the receptivity of a&#xD;
      patient's endometrium to the implantation of an embryo. This may yield additional information&#xD;
      regarding the etiology of a patient's infertility and/or recurrent pregnancy loss. If this&#xD;
      testing is abnormal we may repeat the biopsy after vaginal progesterone supplementation to&#xD;
      see if this normalizes the results. If the microbiome is abnormal we may repeat the biopsy&#xD;
      after oral antibiotics and vaginal probiotics to see if this normalizes your microbiome&#xD;
      results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>abnormal microbiome bacterial sequencing</measure>
    <time_frame>1 month</time_frame>
    <description>The primary outcome will abnormal microbiome results. An abnormal microbiome will be defined as less then 90% lactobacilli on DNA sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>abnormal endometrial receptivity array</measure>
    <time_frame>1 months</time_frame>
    <description>The second primary outcome will be abnormal endometrial receptivity array defined as non-receptive (pre or post receptive) based on RNA sequencing of an endometrial gene array.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>normalized microbiome bacterial sequencing</measure>
    <time_frame>3-6 months</time_frame>
    <description>The primary outcome will be normal microbiome results defined as &gt;90% lactobacilli after oral antibiotics and vaginal probiotics after initially abnormal microbiome results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>normalized endometrial receptivity array</measure>
    <time_frame>3-6 months</time_frame>
    <description>The primary outcome will be normal endometrial receptivity array results defined as receptive after luteal phase progesterone support after initially abnormal endometrial receptivity array results</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Recurrent Pregnancy Loss</condition>
  <condition>Unexplained Infertility</condition>
  <arm_group>
    <arm_group_label>Comparing the microbiome and ERA in RPL and infertility</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm we will assess the uterine environment at the time of implantation in recurrent pregnancy loss patients and unexplained infertility patients and compare the environment in these patient populations to healthy parous controls.&#xD;
We will test the uterine endometrial gene expression using the ERA test and the uterine micro biome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The impact of progesterone and antibiotics/probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, recurrent pregnancy loss and unexplained infertility patients who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Uterine ERA and microbiome testing</intervention_name>
    <description>Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.</description>
    <arm_group_label>Comparing the microbiome and ERA in RPL and infertility</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral antibiotics and vaginal probiotics</intervention_name>
    <description>For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.</description>
    <arm_group_label>The impact of progesterone and antibiotics/probiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent Pregnancy Loss&#xD;
&#xD;
             Inclusion:&#xD;
&#xD;
               -  Age 18-45&#xD;
&#xD;
               -  3 or more SABs including biochemical pregnancies OR 2 or more SABs if one is&#xD;
                  documented to be euploid&#xD;
&#xD;
             Exclusion:&#xD;
&#xD;
               -  irregular menstrual cycles&#xD;
&#xD;
               -  Submucosal fibroid &gt;3cm&#xD;
&#xD;
               -  Stage 3-4 endometriosis&#xD;
&#xD;
               -  BMI &gt;40&#xD;
&#xD;
               -  IUD within the last 3 months&#xD;
&#xD;
          2. Unexplained infertility Patients&#xD;
&#xD;
             Inclusion:&#xD;
&#xD;
               -  TTC x &gt;= 1 year&#xD;
&#xD;
               -  At least one SA with TMS &gt;10 mil within last 2 years&#xD;
&#xD;
               -  At least one patent fallopian tube documented by HSG or SHG&#xD;
&#xD;
               -  Cycle length 25-35 days&#xD;
&#xD;
             Exclusion:&#xD;
&#xD;
               -  Irregular menstrual cycles&#xD;
&#xD;
               -  Submucosal fibroid &gt;3cm&#xD;
&#xD;
               -  Stage 3-4 endometriosis&#xD;
&#xD;
               -  BMI &gt;40&#xD;
&#xD;
               -  IUD within the last 3 months&#xD;
&#xD;
               -  Less then 2 SABs including biochemical pregnancies&#xD;
&#xD;
          3. Healthy control patients&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
          -  Patients who present for fertility preservation, sex selection, same sex couples&#xD;
             needing fertility care, preconception counseling&#xD;
&#xD;
          -  1 or more live births&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Irregular menstrual cycles&#xD;
&#xD;
          -  Submucosal fibroid &gt;3cm&#xD;
&#xD;
          -  Stage 3-4 endometriosis&#xD;
&#xD;
          -  BMI &gt;40&#xD;
&#xD;
          -  IUD within the last 3 months&#xD;
&#xD;
          -  Less then 2 SABs including biochemical pregnancies&#xD;
&#xD;
          -  No history of RPL or infertility&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive Endocrinology and Infertility Center at Stanford University</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara J Churchill, MD</last_name>
      <phone>617-513-4997</phone>
      <email>sarajc@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 1, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ruth Bunker Lathi</investigator_full_name>
    <investigator_title>SSOCIATE PROFESSOR OF OBSTETRICS AND GYNECOLOGY (REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY) AT THE STANFORD UNIVERSITY MEDICAL CENTER</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

